Showing results for:
Abatacept is a indicated for the prophylaxis (prevention) of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor.
Orencia® Abatacept
Vidaza® is FDA approved to treatAdult patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (1.1) Pediatric patients aged 1 month and older with newly diagnosed Juvenile Myelomonocytic Leukemia (JMML).
Vidaza® Azacitidine Onureg®
Denileukin diftitox is FDA approved to treat people who have persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.
Ontak®
Denileukin diftitox
Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
Momelotinib Ojjaara
Nivolumab is FDA approved for the treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and posttransplantation brentuximab vedotin. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Opdivo® Nivolumab
Obecabtagene autoleucel is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Aucatzyl® Obecabtagene autoleucel
Obinutuzumab is FDA-approved In combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL).In combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.In combination with chemotherapy followed by obinutuzumab monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.
Gazyva® Obinutuzumab
Ofatumumab is FDA approved For the treatment of patients who have chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL. In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.
Arzerra® Ofatumumab
Olutasidenib is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
Olutasidenib Rezlidhia™
Omacetaxine mepesuccinate is FDA approved for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).The effectiveness of omacetaxine mepesuccinate was evaluated using a combined group of patients whose cancer progressed after previous treatment with two or more TKIs. All participants were treated with omacetaxine mepesuccinate.
Synribo® Omacetaxine mepesuccinate
Oomidubicel-onlv is indicated for use in adults and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.
Omidubicel-onlv Omisirge®
Pegaspargase is FDA approved in combination with other chemotherapy medications to treat people who have acute lymphoblastic leukemia (ALL).
Oncaspar® PEG-L-asparaginase Pegaspargase
Vincristine is an FDA-approved chemotherapy agent that is used to treat some types of blood cancer as well as some noncancerous conditions. Vincristine may cause hair loss in some patients. After treatment with vincristine has ended, or sometimes even during treatment, normal hair growth should return.
Oncovin® Vincristine